1. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD (2012) Updates in cardiac amyloidosis: a review. J Am Heart Assoc; 1:e000364.
2. Fikrle M, Palečekab, T., Kuchynka, P., Němečeka, E., Bauerovác, L., Straub, J., Ryšaváe, R (2013) Cardiac amyloidosis: a comprehensive review. Cor et vasa; 55:e60-e75.
3. Banypersad SM. The Evolving Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Systemic Amyloidosis (2019) Magn Reson Insights; 12:1178623X19843519.
4. Tang CX, Petersen SE, Sanghvi MM, Lu GM, Zhang LJ (2018) Cardiovascular magnetic resonance imaging for amyloidosis: The state-of-the-art. Trends Cardiovasc Med; 29:83-94.
5. Puntmann VO, Peker E, Chandrashekhar Y, Nagel E (2016) T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review. Circ Res; 119:277-299.
6. Messroghli DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J (2007) Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging; 26:1081-1086.
7. Fontana M, Banypersad SM, Treibel TA, et al (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging; 7:157-165.
8. Banypersad SM, Fontana M, Maestrini V, et al (2015) T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J; 36:244-251.
9. Karamitsos TD, Piechnik SK, Banypersad SM, et al (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging; 6:488-497.
10. Lin L, Li X, Feng J, et al (2018) The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis. J Cardiovasc Magn Reson; 20:2.
11. Ruberg FL (2013) T1 mapping in cardiac amyloidosis: can we get there from here? JACC Cardiovasc Imaging; 6:498-500.